Wells Fargo’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-8,569
| Closed | -$645K | – | 7897 |
|
|
2022
Q2 | $645K | Sell |
8,569
-149,142
| -95% | -$6.63M | ﹤0.01% | 3579 |
|
|
2022
Q1 | $4.24M | Sell |
157,711
-1,204
| -0.8% | -$40.5K | ﹤0.01% | 2596 |
|
|
2021
Q4 | $7.58M | Sell |
158,915
-481,234
| -75% | -$21.5M | ﹤0.01% | 2120 |
|
|
2021
Q3 | $42.5M | Sell |
640,149
-7,035
| -1% | -$501K | 0.01% | 1168 |
|
|
2021
Q2 | $50.5M | Buy |
647,184
+8,047
| +1% | +$595K | 0.01% | 1055 |
|
|
2021
Q1 | $60.5M | Buy |
639,137
+7,637
| +1% | +$908K | 0.01% | 944 |
|
|
2020
Q4 | $76.9M | Buy |
631,500
+20,766
| +3% | +$2.28M | 0.02% | 762 |
|
|
2020
Q3 | $53.4M | Buy |
610,734
+109,081
| +22% | +$7.6M | 0.01% | 837 |
|
|
2020
Q2 | $32.4M | Buy |
501,653
+10,426
| +2% | +$601K | 0.01% | 1076 |
|
|
2020
Q1 | $21.9M | Sell |
491,227
-28,092
| -5% | -$1.49M | 0.01% | 1184 |
|
|
2019
Q4 | $32.3M | Sell |
519,319
-14,247
| -3% | -$678K | 0.01% | 1169 |
|
|
2019
Q3 | $20.1M | Buy |
533,566
+531,784
| +29,842% | +$23.1M | 0.01% | 1440 |
|
|
2019
Q2 | $72K | Buy |
+1,782
| New | +$63.6K | ﹤0.01% | 5431 |
|
Wells Fargo's TPTX Position: Q3 2022 in Review
Wells Fargo sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 8,569 shares — an estimated $645K sold.
Wells Fargo first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $76.9M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Wells Fargo reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Wells Fargo sold 8,569 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $645K.
- Wells Fargo first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Wells Fargo's Turning Point Therapeutics, Inc. Common Stock position peaked at $76.9M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Wells Fargo's 13F filing for Q3 2022, filed 14 Nov 2022.